查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1122368

肺炎球菌疫苗市场：按疫苗类型、分销渠道、地区 - 规模、份额、前景、机会分析，2022-2030

Pneumococcal Vaccines Market, by Vaccine Type, by Distribution Channel and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030
出版日期: | 出版商: Coherent Market Insights | 英文 150 Pages | 商品交期: 2-3个工作天内

价格
简介目录

肺炎球菌感染很常见，通常是轻度感染，例如中耳炎、血液感染、肺炎和细菌性脑膜炎。然而，这种疾病有时会发展成严重和致命的健康问题。肺炎球菌疫苗是一种预防肺炎球菌（致病细菌）的疫苗。有两种类型的疫苗：结合疫苗和多醣疫苗。肺炎球菌疫苗通过肌肉注射给药。结合疫苗对婴儿有效，多醣疫苗对健康成人有效。

市场动态

製药公司不愿投资生产新疫苗，因为回报率很低。这就是为什么供应商专注于参与创新的资助计划，即预先市场承诺 (AMC)。在 AMC 下，国际机构为向新兴国家销售的初始剂量的增量生产成本支付溢价，以换取供应商以长期可持续的价格持续供应疫苗。

例如，默克公司（Merck & Co., Inc.，在美国和加拿大以外也称为默沙东）于 2018 年 4 月宣布，2 我们已启动两项 3 期试验。该公司已启动该疫苗的后续计划，调查不同成人年龄组、新生儿免疫和儿童免疫。该疫苗推出后，将与辉瑞公司已建立的肺炎球菌疫苗 Prefnar-13 竞争。

此外，2018 年 9 月，辉瑞因其新一代 20 价肺炎球菌结合疫苗 (20vPnC) 候选疫苗 PF-06482077 获得美国食品药品监督管理局 (FDA) 的突破性治疗指定 (BTD)。能够在与默克公司的竞争中获得优势，将肺炎球菌疫苗带入美国市场。拟议的疫苗适用于“预防 18 岁及以上成人肺炎球菌血清型引起的侵袭性疾病和肺炎”。 2017 年，美国 FDA 还授予 PF-06482077 快速通道地位。

本研究的主要特点

  • 在本报告中，以2021年为基准年的预测期：2022-2030年，对全球肺炎球菌疫苗市场、市场规模（百万美元）、复合年增长率（CAGR（%））进行了详细分析。
  • 本文阐明了各个细分市场的潜在收入机会，并描述了对该市场有吸引力的投资建议矩阵。
  • 它还提供了有关市场驱动因素和驱动因素、机会、新产品发布和批准、市场趋势、区域前景以及主要参与者采用的竞争策略的重要见解。
  • 根据公司概况、业绩、产品组合、地理分布、分销策略、关键发展和战略等参数，对全球肺炎球菌疫苗市场的主要参与者进行了分析。
  • 本研究涵盖的主要公司包括辉瑞公司、默克公司和葛兰素史克公司。
  • 本报告中的见解将使企业营销人员和高管能够就未来的产品发布、政府举措、技术升级、市场扩张和营销策略做出明智的决策。您将能够做到。
  • 全球肺炎球菌疫苗市场报告迎合了该行业的各种利益相关者，包括投资者、产品製造商、分销商、供应商、研究和咨询公司、新进入者和金融分析师。.
  • 利益相关者可以通过用于分析全球肺炎球菌疫苗市场的各种战略矩阵来促进决策制定。

内容

第 1 章目的和先决条件

  • 调查目的
  • 先决条件
  • 缩写说明

第二章市场展望

  • 报告内容
    • 市场定义和范围
  • 执行摘要
    • 市场快照：按疫苗类型
    • 市场快照：按分销渠道
    • 市场概况：按地区划分
  • 连贯的机会图 (COM)

第 3 章市场动态、监管和趋势分析

  • 市场动态
    • 驱动程序
    • 限制因素
    • 市场机会
  • 影响分析
  • 市场趋势
  • 主要发展状况
  • 管道分析
  • 战略合作
  • 政府的资助和支持
  • 兑换场景
  • GAVI 和 PATH 计划详情
  • 供应短缺情景
  • 流行病学
  • 目标年龄组分析
  • PEST 分析

第 4 章全球肺炎球菌疫苗市场 - 冠状病毒 (COVID-19) 大流行的影响

  • 整体影响
  • COVID-19 对市场的影响

第 5 章全球肺炎球菌疫苗市场，按疫苗类型，2017-2030 年

  • PCV10
  • PCV13
  • PPSV23

第 6 章全球肺炎球菌疫苗市场：按分销渠道，2017-2030 年

  • 医院药房
  • 零售药房
  • 在线药店

第 7 章：2017-2030 年按地区分列的全球肺炎球菌疫苗市场

  • 北美
  • 美国
  • 加拿大
  • 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 其他拉丁美洲地区
  • 欧洲
  • 英国
  • 德国
  • 意大利
  • 法国
  • 西班牙
  • 俄罗斯
  • 其他欧洲
  • 亚太地区
  • 中国
  • 印度
  • 日本
  • 东盟
  • 澳大利亚
  • 韩国
  • 其他亚太地区
  • 中东
  • 海合会
  • 以色列
  • 其他中东
  • 非洲
  • 北非
  • 中非
  • 南非

第 8 章竞争格局

  • 热图分析
  • 公司简介
    • Pfizer,Inc.
    • Merk & Co. Inc.
    • GlaxoSmithKline plc

第九章章节

  • 参考资料
  • 调查方法介绍
  • 关于出版商
简介目录
Product Code: CMI2295

Pneumococcal disease is a common and often mild infection that includes conditions such as middle ear infection, a blood infection, pneumonia, and bacterial meningitis. However, the disease can sometimes result in severe and fatal health problems. Pneumococcal vaccines offer protection against streptococcus pneumonia, which is a causative agent. The vaccine is available in two types as conjugate vaccine and polysaccharide vaccine. Pneumococcal vaccines are administered through intramuscular route. Conjugate vaccines are administered to infants, while polysaccharide vaccines are effective in healthy adults.

Market Dynamics

Pharmaceutical companies are reluctant to invest in production of new vaccines, owing to very less returns. Therefore, vendors are focused on joining Advance Market Commitment (AMC), an innovative financing program. Under AMC, international agencies pay a premium above the incremental production cost for initial doses sold to emerging economies in exchange of continuous supply of vaccines from vendors at sustainable prices for long term.

For instance, in April 2018, Merck & Co., Inc., which is also known as MSD outside of the U.S. and Canada, started two Phase 3 studies of PCV-15 (V114), an investigational polyvalent conjugate vaccine for the prevention of pneumococcal disease. The company initiated follow-up programmes with the vaccine, looking at different adult age groups, neonatal immunization, and childhood immunization. This vaccine, when launched, would compete with Pfizer's established pneumococcal vaccine known as Prevnar-13.

Moreover, in September 2018, Pfizer received Breakthrough Therapy designation (BTD) from the U.S. Food and Drug Administration (FDA) for its 20-Valent Pneumococcal Conjugate Vaccine (20vPnC) candidate, PF-06482077 and got a competitive advantage with Merck & Co to bring a new-generation pneumococcal vaccine to the U.S. market. This proposed vaccine candidate is indicated for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae serotypes in adults aged 18 years and older. The U.S.FDA also granted fast-track status for PF-06482077 in 2017.

Key features of the study:

  • This report provides in-depth analysis of the Global Pneumococcal vaccines market, market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period: 2022 - 2030, considering 2021 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
  • It profiles key players in the global pneumococcal vaccines market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key players covered as a part of this study include, Pfizer, Inc., Merck & Co. Inc., and GlaxoSmithKline plc.
  • Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
  • The global pneumococcal vaccine market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, suppliers, research and consulting firms, new entrants, and financial analysts.
  • Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global pneumococcal vaccines market.

Detailed Segmentation:

  • Global Pneumococcal Vaccine Market, By Vaccine type:
    • PCV10
    • PCV13
    • PPSV23
  • Global Pneumococcal Vaccine Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Pneumococcal Vaccine Market, By Region:
    • North America
      • By Country
    • U.S.
    • Canada
    • Europe
      • By Country
    • U.K.
    • Germany
    • Italy
    • Spain
    • France
    • Russia
    • Rest of Europe
    • Asia Pacific
      • By Country
    • Australia
    • India
    • China
    • Japan
    • ASEAN
    • South Korea
    • Rest of Asia Pacific
    • Latin America
      • By Country
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
    • Middle East
      • By Country
    • GCC
    • Israel
    • Rest of Middle East
    • Africa
      • Others By Country
    • South Africa
    • Central Africa
    • North Africa
  • By Company Profiles
    • Pfizer, Inc.*
      • Company Highlights
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Market Strategies
    • Merck & Co. Inc.
    • GlaxoSmithKline plc.

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Vaccine Type
    • Market Snapshot, By Distribution Channel
    • Market Snapshot, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Market Trends
  • Key Developments
  • Pipeline Analysis
  • Strategic Collaboration
  • Government funding and support
  • Reimbursement Scenario
  • GAVI and PATH Program Details
  • Supply Shortage Scenario
  • Epidemiology
  • Target Age Group Analysis
  • PEST Analysis

4. Global Pneumococcal Vaccines Market- Impact of Coronavirus (Covid-19) Pandemic

  • Overall Impact
  • COVID-19 Impact on the market

5. Global Pneumococcal Vaccines Market, By Vaccine Type, 2017 - 2030, (US$ Million)

  • Overview
    • Market Share Analysis, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • PCV10
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • PCV13
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • PPSV23
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

6. Global Pneumococcal Vaccines Market, By Distribution Channel, 2017 - 2030, (US$ Million)

  • Overview
    • Market Share Analysis, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • Hospital Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Retail Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Online Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

7. Global Pneumococcal Vaccines Market, By Region, 2017 - 2030, (US$ Million)

  • Introduction
    • Market Share Analysis, By Region, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, For Regions, 2017-2030
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
  • U.S.
  • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
  • North Africa
  • Central Africa
  • South Africa

8. Competitive Landscape

  • Heat Map Analysis
  • Company Profile
    • Pfizer,Inc.
  • Company Highlights
  • Product Portfolio
  • Financial Performance
  • Recent Highlights
  • Market Strategies
    • Merk & Co. Inc.
  • Company Highlights
  • Product Portfolio
  • Financial Performance
  • Recent Highlights
  • Market Strategies
    • GlaxoSmithKline plc
  • Company Highlights
  • Product Portfolio
  • Financial Performance
  • Recent Highlights
  • Market Strategies
  • Analyst Views

9. Section

  • References
  • Research Methodology
  • About Us